Target
HPV-16 E6 protein
3 abstracts
Abstract
Characterization of novel compounds that directly bind to and inactivate the HPV E6 protein for treatment of HPV-associated cervical and oropharyngeal cancers.Org: Kovina Therapeutics Inc.,
Abstract
Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).Org: Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, MD, Radiology and Imaging Services, Clinical Center, NIH, Bethesda, MD, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, Office of Research Nursing, OCD, NCI, NIH, Bethesda, MD, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD, Precigen, Inc., Germantown, MD,
Abstract
Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis.Org: Genome Insight Inc., Heavy Ion Research Institute, Korea Advanced Institute of Science and Technology, Lunit Inc.,